case_images: PMC10625822_01
case_images: The transarterial selective internal radiation therapy with yttrium-90 procedure: The angiography microcatheter positioned in the right hepatic artery (black arrow), showing its branches and the hypervascular lesions (white arrows).
case_images: cro-2023-0016-0001-531787_F01.jpg
case_images: PMC10625822_01_cro-2023-0016-0001-531787_F01.jpg
case_images: F1
case_images: Terumo, Shibuya-ku, Tokyo, Japan). Treatment was performed with the administration of 1.2 GBq yttrium-90 resin microspheres (SIR-Spheres , Sirtex Medical Limited, Sydney, NSW, Australia) into the right hepatic artery (shown in Fig. 1).
case_images: The post-transarterial selective internal radiation therapy with yttrium-90 single photon emission-computed tomography (SPECT/CT) demonstrating an intense tracer uptake in the target lesions and little uptake in the normal liver.
case_images: cro-2023-0016-0001-531787_F02.jpg
case_images: PMC10625822_01_cro-2023-0016-0001-531787_F02.jpg
case_images: F2
case_images: There were no complications, and the patient was subsequently discharged from the hospital 1 day after the procedure (shown in Fig. 2).
case_images: The timeline of patient's therapies. CR, complete response; ddMVAC, methotrexate, vinblastine, doxorubicin, and cisplatin; PD, progressive disease; RLN, retroperitoneal lymph node; SBRT, stereotactic body radiotherapy; SIRT, selective internal radiation therapy; SUV, standardized uptake value.
case_images: cro-2023-0016-0001-531787_F03.jpg
case_images: PMC10625822_01_cro-2023-0016-0001-531787_F03.jpg
case_images: F3
case_images: The complete therapeutic management is summarized in Figure 3 (shown in Fig. 3).
case_images: The axial positron emission tomography-computed tomography with 18-fluorodeoxyglucose (18-FDG PET-CT) image performed in October 2021 showing regression of the hepatic lesions with complete resolution of FDG uptake.
case_images: cro-2023-0016-0001-531787_F04.jpg
case_images: PMC10625822_01_cro-2023-0016-0001-531787_F04.jpg
case_images: F4
case_images: At the last clinical evaluation in June 2022, the patient had no clinical symptoms, and the last imaging follow-up in April 2021 using PET/CT scan showed complete response (shown in Fig. 4).